Regeneron Pharmaceuticals
REGN
1,291 hedge funds and large institutions have $59.1B invested in Regeneron Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 139 funds opening new positions, 528 increasing their positions, 453 reducing their positions, and 147 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 528 | Existing positions reduced: 453
7% more funds holding in top 10
Funds holding in top 10: 14 → 15 (+1)
0.26% more ownership
Funds ownership: 86.53% → 86.78% (+0.26%)
3% less call options, than puts
Call options by funds: $974M | Put options by funds: $1B
5% less first-time investments, than exits
New positions opened: 139 | Existing positions closed: 147
2% less funds holding
Funds holding: 1,318 → 1,291 (-27)
11% less capital invested
Capital invested by funds: $66.7B → $59.1B (-$7.51B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$381M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$269M |
| 3 |
Two Sigma Investments
New York
|
+$232M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$209M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$180M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$964M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$578M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$514M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$413M |
| 5 |
Morgan Stanley
New York
|
-$123M |
REGN Hedge Fund Activity: Q1 2025 in Review
1,291 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2025, worth a combined $59.1B — down 11% from $66.7B a quarter earlier.
Sellers outnumbered buyers: 147 funds closed out of REGN and 139 opened new positions — a net loss of 8 holders — while 453 trimmed existing stakes and 528 added.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $381M. The largest seller was JP Morgan Chase, cutting an estimated $964M.
- 1,291 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2025, down from 1,318 in Q4 2024.
- Funds reported $59.1B of Regeneron Pharmaceuticals stock for Q1 2025, down 11% quarter-over-quarter.
- 139 funds opened new Regeneron Pharmaceuticals positions in Q1 2025 and 147 closed out, a net change of -8 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2025 was Two Sigma Advisers, an estimated $381M added.
- The largest Regeneron Pharmaceuticals seller in Q1 2025 was JP Morgan Chase, an estimated $964M sold.
Based on aggregated 13F filings for Q1 2025.